Should the Belsomra (suvorexant) dose be increased for a patient currently taking 5 mg at bedtime who is experiencing insomnia?

Should Belsomra be Increased from 5 mg?

Yes, increase the Belsomra dose to 10 mg for this patient experiencing persistent insomnia on 5 mg at bedtime. The FDA-approved dosing strategy explicitly supports this approach when the lower dose is well-tolerated but ineffective 1.

Dosing Algorithm

The FDA label provides clear guidance on dose escalation 1:

• Starting dose: 10 mg is the recommended initial dose (not 5 mg)
• If 10 mg is well-tolerated but not effective: Increase to higher doses
• Maximum dose: 20 mg once nightly
• Your patient's situation: Currently on 5 mg (below standard starting dose) with inadequate response

Specific Action Steps

1. Increase to 10 mg immediately - This is actually the FDA-recommended starting dose, so you're simply moving to the standard therapeutic dose 1

2. If 10 mg remains ineffective after adequate trial (typically 1-2 weeks):

   • Consider increasing to 15 mg or 20 mg
   • Maximum dose is 20 mg once nightly 1

3. Special considerations before dose escalation:

   • Obese women: Higher exposure risk - use caution with doses above 10 mg 1
   • Concurrent CYP3A inhibitors: If on moderate CYP3A inhibitors, keep dose ≤10 mg 1
   • CNS depressants: If taking other sedatives/alcohol, consider lower doses 1

Evidence Supporting Suvorexant Use

The American Academy of Sleep Medicine guidelines support suvorexant for sleep maintenance insomnia, though their recommendations were based on trials using 10,15/20, and 20 mg doses - not 5 mg 2. This reinforces that 5 mg is subtherapeutic for most patients.

Efficacy Data

• Suvorexant demonstrates significant improvements in sleep onset latency, wake after sleep onset, and sleep efficiency at therapeutic doses 3
• The 5 mg dose is primarily reserved for patients on moderate CYP3A inhibitors, not as a standard therapeutic dose 1

Critical Safety Considerations

Before increasing the dose, verify:

• Timing: Patient takes medication with ≥7 hours remaining before planned awakening 1
• Food intake: Not taking with or immediately after meals (delays effect) 1
• Alcohol: Patient must avoid alcohol completely 1
• Other CNS depressants: Review all medications for additive sedation risk 1

Common Pitfall to Avoid

Do not keep patients on 5 mg indefinitely if ineffective. The 5 mg dose exists primarily for drug interaction management, not as a standard maintenance dose. The FDA explicitly states: "If the 10 mg dose is well-tolerated but not effective, the dose can be increased" 1. Your patient is below even the standard starting dose.

Monitoring After Dose Increase

• Next-day somnolence: Most common adverse effect (NNH = 13 for higher doses) 4
• Driving impairment: Counsel about potential next-day effects, especially at 20 mg 1
• Response assessment: Evaluate efficacy after 1-2 weeks at new dose

The evidence strongly supports dose escalation in this scenario - keeping a patient on a subtherapeutic dose when they have persistent insomnia is not evidence-based practice 1.